Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries an Avi tag (Avitag™) at the N-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 79.8 kDa. The protein migrates as 70-85 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Rat Transferrin R Protein, Avitag,His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Biotinylated Rat Transferrin R Protein, Avitag,His Tag (Cat. No. TFR-R82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Mouse Transferrin Protein, Mouse IgG2a Fc Tag (Cat. No. TRN-M525b) with a linear range of 0.2-6 ng/mL (QC tested).
Immobilized Mouse Transferrin Protein, Mouse IgG2a Fc Tag (Cat. No. TRN-M525b) at 2 μg/mL (100 μL/well) can bind Biotinylated Rat Transferrin R Protein, Avitag,His Tag (Cat. No. TFR-R82E3) with a linear range of 0.5-31 ng/mL (Routinely tested).
Price(USD) : $360.00
Price(USD) : $1420.00
Price(USD) : $35.00
Price(USD) : $140.00
Price(USD) : $50.00
Price(USD) : $125.00
Price(USD) : $140.00
Price(USD) : $235.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Pabinafusp alfa | JR-141 | Approved | Jcr Pharmaceuticals Co Ltd | Japan | Mucopolysaccharidosis II | Jcr Pharmaceuticals Co Ltd | 2021-03-23 | Mucopolysaccharidosis II | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Human apotransferrin (Sanquin Blood Supply Foundation) | Phase 3 Clinical | Sanquin Plasma Products Bv | Iron Metabolism Disorders; beta-Thalassemia | Details | |
Delpacibart eteddesiran | AOC-1001; AOC 1001 | Phase 3 Clinical | Avidity Biosciences Inc | Myotonic Disorders; Genetic Diseases, Inborn; Musculoskeletal Diseases; Muscular Disorders, Atrophic; Myotonic Dystrophy; Muscular Atrophy; Heredodegenerative Disorders, Nervous System; Muscular Diseases; Neuromuscular Diseases; Nervous System Diseases; Muscular Dystrophies; Neurodegenerative Diseases; Myotonia | Details |
CX-2029 | ABBV-2029; ABBV-CX-2029; CX-2029 | Phase 2 Clinical | Abbvie Inc, Cytomx Therapeutics Inc | Solid tumours; Head and Neck Neoplasms; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung | Details |
DYNE-251 | DYNE251 | Phase 2 Clinical | Dyne Therapeutics Inc | Muscular Dystrophy, Duchenne | Details |
JR-446 | JR-446 | Phase 2 Clinical | Jcr Pharmaceuticals Co Ltd, Medipal Holdings Corp | Mucopolysaccharidosis III | Details |
JR-441 | JR-441 | Phase 2 Clinical | Jcr Pharmaceuticals Co Ltd | Mucopolysaccharidosis III | Details |
Lepunafusp alfa | JR-171 | Phase 2 Clinical | Jcr Pharmaceuticals Co Ltd | Mucopolysaccharidosis I | Details |
PPMX-T003 | PPMX-T003 | Phase 2 Clinical | Perseus Proteomics Inc | Leukemia; Polycythemia Vera | Details |
Trontinemab | RO-7126209; RG-6102 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Alzheimer Disease | Details |
INA-03 | INA03 | Phase 1 Clinical | Inatherys | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
KK-2260 | KK2260; KK-2260 | Phase 1 Clinical | Kyowa Kirin Co Ltd | Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
ABX-1100 | ABX-1100 | Phase 1 Clinical | Aro Biotherapeutics Co | Glycogen Storage Disease Type II | Details |
This web search service is supported by Google Inc.